Enliven Therapeutics, Inc. (ELVN) News
Track canonical SquawkNews coverage tagged to ELVN, Enliven Therapeutics, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 4 indexed stories across 4 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
ELVN ELVN - Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update
ELVN ELVN - Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update
EARNINGS | Aug 05, 2026, 08:06 PM UTC
L
Enliven Therapeutics Insider Sold Shares Worth $504,903, According to a Recent SEC Filing
() -- Lori Anne Kunkel, Director, on July 06, 2026, sold 10,000 shares in Enliven Therapeutics (ELVN) for $504,903. Following the Form 4 filing with the SEC, Kunkel has control over a total of 41,884 common shares of the
REGULATION | Jul 08, 2026, 09:22 PM UTC
L
Stifel Maintains Buy on Enliven Therapeutics, Raises Price Target to $80
Stifel analyst Dara Azar maintains Enliven Therapeutics (NASDAQ: ELVN ) with a Buy and raises the price target from $60 to $80.
EQUITY | Jul 01, 2026, 02:02 PM UTC
M
Jones Trading Maintains Buy on Enliven Therapeutics, Raises Price Target to $70
Jones Trading analyst Boris Peaker maintains Enliven Therapeutics (NASDAQ: ELVN ) with a Buy and raises the price target from $45 to $70.
EQUITY | Jun 29, 2026, 03:34 PM UTC